LY2886721 (LY-2886721)是可口服、可透过血脑屏障的β位淀粉样蛋白前体蛋白裂解酶1 (BACE1)抑制剂，IC₅₀值20.3 nM，能通过抑制β-淀粉样蛋白合成来减慢阿尔茨海默症的临床进展。

参考文献

[1] May PC, et al. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210.

[2] Audrain M, et, al. βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease. Cereb Cortex. 2018 Nov 1;28(11):3976-3993.

冰袋运输。粉末直接保存于-25~-15℃，有效期3年。建议溶解分装后于-25~-15℃干燥保存，避免反复冻融。